Alto is a full-service digital pharmacy with roughly $1 billion in annualized revenue managed by Alicia Boler, former head of global fulfillment at Amazon.
As part of this partnership, Alto becomes a key distributor for the pharmaceutical giant’s newly launched direct-to-consumer (D2C) platform, PfizerForAll. The platform is designed to streamline access to essential medication and healthcare services, providing patients with a direct and simplified pathway to prescriptions, vaccines, and diagnostic tests—bypassing many of the traditional complexities of the U.S. healthcare system.
Alto Pharmacy, as a critical partner in this initiative, will manage the delivery of prescription medication, offering both pickup and home delivery options. PfizerForAll’s initial focus includes treatment for common conditions like migraines, COVID-19, and the flu, along with providing access to vaccines for respiratory illnesses.
This partnership represents a significant milestone in Pfizer’s D2C strategy, aimed at reducing barriers to healthcare access and improving patient outcomes. Alto Pharmacy’s role in this collaboration highlights its commitment to providing affordable, high-quality medication directly to patients. Additionally, Alto is using industry-leading automation technology to reduce the administrative burden on pharmacists, allowing them to operate at the top of their licenses to improve the quality of patient care.
Alto has already teamed-up with other major pharmaceutical companies such as the Mark Cuban Cost Plus Drugs Company, to deliver low-cost medication across the United States by collaborating with these innovative firms.
For the second year in a row, Alto was named on the 2024 CNBC Disruptor 50 list. This recognizes private companies chasing some of the market’s biggest opportunities. This recognition highligths Alto’s focus on transforming the healthcare landscape and providing greater accessibility to life-saving medication.
Sources: Fierce Pharma, Alto Pharmacy, CNBC
Comments